Patents

현재 추적 중인 미토콘드리아 전달 및 이식 관련 특허 포트폴리오는 총 12건입니다.

1. 🔴 고위험 특허 (4건)

Mitochondrial transplantation and use thereof in ocular and neurological diseases (Mor Research Applications Ltd / Sheba Medical Center - US12478644B2 (US20220168358A1) [GRANTED])
FTO 이슈 및 분석: HIGH FTO Concern: Granted broad claims on isolated mitochondria ocular administration; potential freedom-to-operate obstacle for eye indications.
Human stem cells enriched with functional exogenous mitochondria and therapeutic uses thereof (MAT Platform) (Minovia Therapeutics Ltd. - US11491188B2 (WO2019159170A1) [GRANTED])
FTO 이슈 및 분석: HIGH FTO Concern: Foundational granted patent on ex-vivo cell enrichment with exogenous mitochondria for systemic and hematological diseases.
Mitochondrial augmentation therapy of muscle diseases, metabolic disorders, and Pearson syndrome (Minovia Therapeutics Ltd. - WO2020021535A1 (US20210290680A1) [PUBLISHED])
FTO 이슈 및 분석: HIGH FTO Concern: Covers intravenous and intramyocardial/intramuscular infusion protocols.
Pharmaceutical composition comprising isolated allogeneic mitochondria for treating inflammatory and autoimmune diseases (PN-101) (Paean Biotechnology Inc. - WO2021118228A1 (KR102435492B1) [GRANTED])
FTO 이슈 및 분석: HIGH FTO Concern: Key granted patent on allogeneic UC-MSC isolated mitochondria formulation and preservation buffers.

2. 🟡 중위험 관찰 대상 (4건)

Method for preparing mitochondria with enhanced intracellular transfer efficiency and membrane potential stability (Paean Biotechnology Inc. - WO2022240243A1 (US20240238356A1) [PUBLISHED])
기술 동향 및 경과: MEDIUM FTO Concern: Manufacturing process and stabilization formulation.
Therapeutic Use of Mitochondria and Combined Mitochondrial Agent for Ischemic Tissue Protection and Regeneration (Children's Medical Center Corporation (Boston Children's Hospital) - US10967000B2 (US20180057610A1) [GRANTED])
기술 동향 및 경과: MEDIUM FTO Concern / Foundational Prior Art: First-generation naked autologous mitochondria injection for ischemia reperfusion injury.
Erythrocyte-membrane-vesicle-encapsulated mitochondria delivery system (Mito-EMVs) and preparation method thereof (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - CN114533816A (WO2023216890A1) [PUBLISHED])
기술 동향 및 경과: MEDIUM FTO Concern: Biomimetic vesicle carrier encapsulation prior art.
pHLIP cell-surface epitope tethering and acid-triggered organelle delivery (Yale University / University of Rhode Island - US20200246420A1 [PUBLISHED])
기술 동향 및 경과: MEDIUM FTO Concern: Acid-targeting peptide tethering.

3. 🛡️ 자체 플랫폼 및 저위험 선행기술 (4건)

Cell-type-targeted mitochondrial transplantation using bispecific binders (MitoCatch Platform) (Institute of Molecular and Clinical Ophthalmology Basel (IOB) - PCT (Pending - IOB) [PENDING])
플랫폼 분석: Subject core technology (MitoCatch). Foundation for cell-selective organelle transfer.
Apparatus and methods for local micro-injection and delivery of isolated mitochondria to myocardial tissue (Children's Medical Center Corporation (Boston Children's Hospital) - US20210353684A1 [PUBLISHED])
플랫폼 분석: LOW FTO Concern: Device/surgical delivery tool claims.
Bispecific nanobody platform for targeted organelle and protein conjugate intracellular delivery (ABL Bio Inc. / Sanofi - WO2023150600A1 [PUBLISHED])
플랫폼 분석: LOW FTO Concern: General background nanobody conjugation prior art.
Multivalent and multispecific single domain antibody polypeptides (Ablynx N.V. (Sanofi) - EP3049439A1 (US20160251440A1) [GRANTED])
플랫폼 분석: LOW FTO Concern: Core nanobody architecture expired or foundational patents.